Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Large B-Cell, Diffuse 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Burkitt Lymphoma 10Recurrence 9Lymphoma, Follicular 5Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Leukemia 3Neoplasm, Residual 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 23blinatumomab 18Cytarabine 16fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Daunorubicin 7Mercaptopurine 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Drug Therapy 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm, Residual × tisagenlecleucel × Clear all
NCT03876769 2026-04-17

CASSIOPEIA

Novartis

Phase 2 Active not recruiting
121 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT02529813 2022-06-30

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡